文献速递脑血管病神经重症与神经感染

不同口服抗凝药相关脑出血的结局比较

Outcome of intracerebral hemorrhage associated with different oral anticoagulants.
PubMed 文献 · Neurology · 2017-04-05

这项国际多中心汇总分析纳入500例口服抗凝药相关脑出血患者,比较非维生素K拮抗剂口服抗凝药(NOAC)与维生素K拮抗剂(VKA)相关脑出血的90天死亡率、功能结局、血肿体积和血肿扩大。结果显示两组基线血肿体积、血肿扩大率、90天死亡率和出院功能结局均相似。

要点

  • NOAC-ICH与VKA-ICH的90天全因死亡率无差异(33% vs 31%)。
  • 两组血肿扩大率无差异(40% vs 34%)。
  • 基线血肿体积和出院功能结局在两组间相似。

核心结论

  • NOAC-ICH与VKA-ICH在基线血肿体积、血肿扩大、90天死亡率和功能结局方面相似。

研究设计与样本

  • 国际多中心汇总分析,纳入500例口服抗凝药相关脑出血患者(97例NOAC-ICH,403例VKA-ICH)。
  • 采用Cox比例风险模型比较90天全因死亡率,并校正年龄、性别、基线GCS评分、出血部位、血肿体积对数、脑室内出血体积和颅内手术。
  • 使用共享脆弱项处理异质性,功能结局采用多变量logistic回归分析。

主要发现

  • NOAC-ICH基线血肿体积中位数14.4 mL(IQR 3.6-38.4),VKA-ICH为10.6 mL(IQR 4.0-27.9),p=0.78。
  • 90天全因死亡率NOAC-ICH为33%,VKA-ICH为31%(p=0.64);校正后Cox风险比0.93(95%CI 0.52-1.64,p=0.79)。
  • 血肿扩大率NOAC-ICH为29/48(40%),VKA-ICH为93/140(34%),p=0.45。
  • 出院功能结局(mRS≤2)NOAC-ICH vs VKA-ICH的OR为0.47(95%CI 0.18-1.19,p=0.11)。

临床怎么用

  • 对于口服抗凝药相关脑出血患者,NOAC与VKA相关脑出血的急性期结局相似,临床管理可参考相应抗凝逆转策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In an international collaborative multicenter pooled analysis, we compared mortality, functional outcome, intracerebral hemorrhage (ICH) volume, and hematoma expansion (HE) between non-vitamin K antagonist oral anticoagulation-related ICH (NOAC-ICH) and vitamin K antagonist-associated ICH (VKA-ICH). METHODS: We compared all-cause mortality within 90 days for NOAC-ICH and VKA-ICH using a Cox proportional hazards model adjusted for age; sex; baseline Glasgow Coma Scale score, ICH location, and log volume; intraventricular hemorrhage volume; and intracranial surgery. We addressed heterogeneity using a shared frailty term. Good functional outcome was defined as discharge modified Rankin Scale score ≤2 and investigated in multivariable logistic regression. ICH volume was measured by ABC/2 or a semiautomated planimetric method. HE was defined as an ICH volume increase >33% or >6 mL from baseline within 72 hours. RESULTS: We included 500 patients (97 NOAC-ICH and 403 VKA-ICH). Median baseline ICH volume was 14.4 mL (interquartile range [IQR] 3.6-38.4) for NOAC-ICH vs 10.6 mL (IQR 4.0-27.9) for VKA-ICH (p = 0.78). We did not find any difference between NOAC-ICH and VKA-ICH for all-cause mortality within 90 days (33% for NOAC-ICH vs 31% for VKA-ICH [p = 0.64]; adjusted Cox hazard ratio (for NOAC-ICH vs VKA-ICH) 0.93 [95% confidence interval (CI) 0.52-1.64] [p = 0.79]), the rate of HE (NOAC-ICH n = 29/48 [40%] vs VKA-ICH n = 93/140 [34%] [p = 0.45]), or functional outcome at hospital discharge (NOAC-ICH vs VKA-ICH odds ratio 0.47; 95% CI 0.18-1.19 [p = 0.11]). CONCLUSIONS: In our international collaborative multicenter pooled analysis, baseline ICH volume, hematoma expansion, 90-day mortality, and functional outcome were similar following NOAC-ICH and VKA-ICH.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Wilson D, Seiffge DJ, Traenka C, et al. Outcome of intracerebral hemorrhage associated with different oral anticoagulants. Neurology. 2017. PMID: 28381513. doi:10.1212/WNL.0000000000003886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。